Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

Report Summary

GBI Research, the leading business intelligence provider, has released its latest report, Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy. The report also provides the share of generics in global market as well as for each indication. It also provides the treatment flow algorithm for each of the five indications. The report examines the global musculoskeletal disorders treatment usage patterns. In addition, our research details the geographical distribution of musculoskeletal disorders markets across the US, the top five countries of Europe, and Japan.The report also includes insight into the musculoskeletal disorders R&D product pipeline and explores the competitive landscape, including major players in the musculoskeletal disorders therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the market in recent years. GBI Research’s analysis shows that the overall global musculoskeletal disorders therapeutics market for the five indications (which includes rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy) was valued at $33.4 billion in 2010, indicating a CAGR of 5.7% over the previous year. GBI Research forecasts the market to grow at a CAGR of 7.3% between 2010 and 2017, to record a sales value of $54.8 billion by 2017. The growth in major markets such as the US and the top five countries in the EU and Japan were driven by new developments that created more options in the treatment of rheumatoid arthritis, osteoporosis, osteoarthritis, muscular dystrophy and low back pain. The global musculoskeletal disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). The future of the market is based on the success of the drugs in the pipeline; while the current musculoskeletal disorders market pipeline holds strong prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the generic share continues to rise in the market.

Scope

•  Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
•  Annualized market data for the market from 2002 to 2010, with forecasts to 2017 for the three indications – rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy.
•  Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
•  Share of the generics in the global musculoskeletal disorders therapeutics market and for the market of each indication that is covered in the report.
•  Key drivers and restraints that have had a significant impact on the market.
•  The competitive landscape of the market, including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Eli Lilly, Johnson & Johnson, Amgen Inc. and Abbott Laboratories.
•  Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the musculoskeletal disorders therapeutics market.

Reasons to Buy

• Align your product portfolio to the markets with high growth potential.
• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Musculoskeletal Disorders Therapeutics Market to 2017: Executive Summary
2.1 Global Musculoskeletal Disorders Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise
2.2 The Top Three Companies in Musculoskeletal Disorders Therapeutics Market Account for 43% of the Market Share
2.3 Unmet Need for Better Management of Musculoskeletal Diseases and Potential for Future Growth is Driving Companies to Invest in Research and Development

3 Musculoskeletal Disorders Therapeutics Market to 2017: Introduction
3.1 GBI Research Report Guidance

4 Musculoskeletal Disorders Therapeutics Market to 2017: Market Overview
4.1 Introduction
4.1.1 Revenue
4.1.2 Annual Cost of Treatment
4.1.3 Treatment Usage Pattern

5 Musculoskeletal Disorders Therapeutics Market to 2017: Geographical Landscape
5.1 Revenue Analysis by Geography
5.2 The US
5.2.1 Revenue
5.2.2 Annual Cost of Treatment
5.2.3 Treatment Usage Patterns
5.3 Top Five Countries of Europe
5.3.1 Revenue
5.3.2 Annual Cost of Treatment
5.3.3 Treatment Usage Patterns
5.4 Japan
5.4.1 Revenue
5.4.2 Annual Cost of Treatment
5.4.3 Treatment Usage Patterns

6 Musculoskeletal Disorders Therapeutics Market to 2017: Therapeutic Landscape
6.1 Rheumatoid Arthritis Therapeutics Market
6.1.1 Introduction
6.1.2 Revenue
6.1.3 Annual Cost of Treatment
6.1.4 Treatment Usage Pattern
6.1.5 Treatment Flow Algorithm
6.1.6 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market
6.2 Osteoporosis Therapeutics
6.2.1 Introduction
6.2.2 Revenue
6.2.3 Annual Cost of Treatment
6.2.4 Treatment Usage Patterns
6.2.5 Treatment Flow Algorithm
6.2.6 Drivers and Barriers for Osteoporosis Therapeutics Market
6.3 Osteoarthritis Therapeutics
6.3.1 Introduction
6.3.2 Revenue
6.3.3 Annual Cost of Treatment
6.3.4 Treatment Usage Patterns
6.3.5 Treatment Flow Algorithm
6.3.6 Drivers and Barriers for Osteoarthritis Therapeutics Market
6.4 Low Back Pain Therapeutics
6.4.1 Introduction
6.4.2 Revenue
6.4.3 Annual Cost of Treatment
6.4.4 Treatment Usage Patterns
6.4.5 Treatment Flow Algorithm
6.4.6 Drivers and Barriers for Low Back Pain Therapeutics Market
6.5 Muscular Dystrophy Therapeutics
6.5.1 Introduction
6.5.2 Revenue
6.5.3 Annual Cost of Treatment
6.5.4 Treatment Usage Patterns
6.5.5 Treatment Flow Algorithm
6.5.6 Drivers and Barriers for Muscular Dystrophy Therapeutics Market

7 Musculoskeletal Disorders Therapeutics Market to 2017: Pipeline Analysis
7.1 Introduction
7.2 Musculoskeletal Disorders Therapeutics Market – Pipeline Assessment by Clinical Phase of Development
7.2.1 NDA Filed Molecules
7.2.2 Phase III
7.2.3 Phase II
7.2.4 Phase I
7.2.5 Preclinical Phase
7.2.6 Discovery Phase
7.3 Profiles of Promising Molecules in the Musculoskeletal Disorders Therapeutics Market
7.3.1 YM529 (minodronate)
7.3.2 EX101 (alendronate)
7.3.3 MAbThera (rituximab)
7.3.4 Actemra (tocilizumab)
7.3.5 Simponi
7.3.6 Naproxcinod
7.3.7 Iguratimod

8 Musculoskeletal Disorders Therapeutics Market to 2017: Competitive Profiling
8.1 Competitive Profiling
8.1.1 Abbott Laboratories
8.1.2 Johnson & Johnson
8.1.3 Amgen Inc.
8.1.4 Pfizer Inc
8.1.5 Eli Lilly and Company

9 Musculoskeletal Disorders Therapeutics Market to 2017: Strategic Consolidations
9.1 Mergers and Acquisitions
9.1.1 Segmentation by Deal Value
9.1.2 Segmentation by Geography
9.2 Co-development Deals
9.2.1 Summary of Co-development Deals
9.3 Licensing Deals
9.3.1 Summary of Licensing Deals

10 Musculoskeletal Disorders Therapeutics Market to 2017: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.4 Therapeutic Landscape
10.4.1 Epidemiology-based Forecasting
10.4.2 Market Size by Geography
10.5 Geographical Landscape
10.6 Pipeline Analysis
10.7 Competitive Landscape
10.7.1 Expert Panel Validation
10.8 Contact Us
10.9 Disclaimer
10.10 Sources

List of Tables

Table 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 2: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 4: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
Table 6: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
Table 7: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
Table 8: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
Table 9: Musculoskeletal Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2010
Table 10: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017
Table 11: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010
Table 12: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017
Table 13: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2010
Table 14: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2010-2017
Table 15: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue ($bn), 2002-2010
Table 16: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017
Table 17: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2002-2010
Table 18: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2010-2017
Table 19: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010
Table 20: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017
Table 21: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2010
Table 22: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2010-2017
Table 23: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2010
Table 24: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017
Table 25: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010
Table 26: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017
Table 27: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010
Table 28: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017
Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017
Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
Table 37: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 38: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 39: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
Table 40: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
Table 41: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 42: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 43: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2002-2010
Table 44: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2010-2017
Table 45: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 46: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 47: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
Table 48: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
Table 49: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 50: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 51: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010
Table 52: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017
Table 53: Low Back Pain Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 54: Low Back Pain Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 55: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
Table 56: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
Table 57: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 58: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 59: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010
Table 60: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017
Table 61: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2002-2010
Table 62: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017
Table 63: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 64: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 65: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 66: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 67: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s), 2002-2010
Table 68: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s), 2010-2017
Table 69: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules, July 2011
Table 70: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase III, July 2011
Table 71: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase II, July 2011
Table 72: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase I, July 2011
Table 73: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase, July 2011
Table 74: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Discovery Phase, July 2011
Table 75: Musculoskeletal Disorders Therapeutics Market, Global, M&A, 2009-2011
Table 76: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Value ($m) 2009-2011
Table 77: Musculoskeletal Disorders Therapeutics Market, Co-development, By Geography, 2009-2011
Table 78: Musculoskeletal Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011

List Of Figures

Figure 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017
Figure 2: Musculoskeletal Disorders Therapeutics Market, Global, Market Share Top Three Companies, 2010
Figure 3: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 4: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
Figure 6: Musculoskeletal Disorders Therapeutics Market, Global, Diseased Population (millions), 2002-2017
Figure 7: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017
Figure 8: Musculoskeletal Disorders Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017
Figure 9: Musculoskeletal Disorders Therapeutics Market, Global, Prescription Population (millions), 2002-2017
Figure 10: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
Figure 11: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017
Figure 12: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017
Figure 13: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2017
Figure 14: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017
Figure 15: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2002-2017
Figure 16: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017
Figure 17: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2017
Figure 18: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2017
Figure 19: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017
Figure 20: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2017
Figure 21: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 22: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
Figure 23: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Segmentation
Figure 24: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 25: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
Figure 26: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
Figure 27: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
Figure 28: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
Figure 29: Rheumatoid Arthritis Therapeutics Market , Global, Prescription Population (Millions), 2002-2017
Figure 30: Musculoskeletal Disorders Therapeutics Market, Global, Rheumatoid Arthritis Pain, Treatment Algorithm
Figure 31: Rheumatoid Arthritis, Market Drivers and Barriers, 2010-2017
Figure 32: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 33: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
Figure 34: Osteoporosis Therapeutics Market, Global, Branded and Generics Share, 2010 & 2017
Figure 35: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 36: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2002-2017
Figure 37: Osteoporosis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
Figure 38: Osteoporosis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
Figure 39: Osteoporosis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
Figure 40: Osteoporosis Therapeutics Market , Global, Prescription Population (Millions), 2002-2017
Figure 41: Musculoskeletal Disorders Therapeutics Market, Global, Osteoporosis, Treatment Algorithm
Figure 42: Osteoporosis, Market Drivers and Barriers, 2010-2017
Figure 43: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 44: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
Figure 45: Osteoarthritis Therapeutics Market, Global, Branded and Generics Share, 2010 & 2017
Figure 46: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 47: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017
Figure 48: Osteoarthritis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
Figure 49: Osteoarthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
Figure 50: Osteoarthritis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
Figure 51: Osteoarthritis Therapeutics Market, Global, Prescription Population (Millions), 2002-2017
Figure 52: Musculoskeletal Disorders Therapeutics Market, Global, Osteoarthritis, Treatment Algorithm
Figure 53: Osteoarthritis, Market Drivers and Barriers, 2010-2017
Figure 54: Low Back Pain Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 55: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
Figure 56: Low Back Pain Therapeutics Market, Global, Branded and Generics Share (%), 2010 & 2017
Figure 57: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 58: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017
Figure 59: Low Back Pain Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
Figure 60: Low Back Pain Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
Figure 61: Low Back Pain Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
Figure 62: Low Back Pain Therapeutics Market, Global, Prescription Population (Millions), 2002-2017
Figure 63: Musculoskeletal Disorders Therapeutics Market, Global, Low Back Pain, Treatment Algorithm
Figure 64: Low Back Pain, Market Drivers and Barriers, 2010-2017
Figure 65: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017
Figure 66: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 67: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 68: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s), 2002-2017
Figure 69: Muscular Dystrophy Therapeutics Market, Global, Diseased Population (000’s), 2002-2017
Figure 70: Muscular Dystrophy Therapeutics Market, Global, Treatment Seeking Population (000’s), 2002-2017
Figure 71: Muscular Dystrophy Therapeutics Market, Global, Diagnosed Population (000’s), 2002-2017
Figure 72: Muscular Dystrophy Therapeutics Market, Global, Prescription Population (000’s), 2002-2017
Figure 73: Musculoskeletal Disorders Therapeutics Market, Global, Muscular Dystrophy, Treatment Algorithm
Figure 74: Muscular Dystrophy, Market Drivers and Barriers, 2010-2017
Figure 75: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
Figure 76: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
Figure 77: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Abbott Laboratories, 2010
Figure 78: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Johnson & Johnson, 2010
Figure 79: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Amgen Inc., 2010
Figure 80: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Pfizer, 2010
Figure 81: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Eli Lilly, 2010
Figure 82: Musculoskeletal Disorders Therapeutics Market, Global, Deals by Indications, 2009-2011
Figure 83: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Value ($m) 2009-2011
Figure 84: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Geography, 2009-2011
Figure 85: Musculoskeletal Disorders Therapeutics Market, Co-development, By Indications, 2009-2011
Figure 86: Musculoskeletal Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011
Figure 87: GBI Research Market Forecasting Model